Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 2

Year

2015 2

Keywords

pharmacogenetics 2

acute lymphoblastic leukemia 1

big data 1

biosensors 1

body-sensing networks 1

clinical decision support systems 1

genomics 1

implantable sensors 1

mHealth 1

pharmacogenomics 1

open ︾

Search scope:

排序： Display mode:

Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2015, Volume 9, Issue 1, Pages 1-9 doi: 10.1007/s11684-015-0381-3

Abstract:

With the cure rate of childhood acute lymphoblastic leukemia (ALL) approaching 90%, further improvement in the treatment outcome and quality of life of patients will require better understanding of the mechanisms of drug resistance, identifying new leukemic cell genetic lesions that are amendable to available target therapy, and optimizing treatment based on host pharmacodynamics and pharmacogenomics. Deeper characterization of leukemic cell genetic abnormalities has discovered new subtypes of leukemia such as early T-cell precursor ALL and Philadelphia chromosome-like ALL, and identified many genomic alterations that have diagnostic, prognostic, or therapeutic implications. In this regard, several novel fusion transcripts are responsive to ABL tyrosine kinase inhibitors and potentially to JAK inhibitors. Genome-wide analyses have also unraveled the role of inherited cancer predisposing genes and small nucleotide polymorphisms of several genes in the development of childhood ALL. These advances promise to lead to more sophisticated personalized treatment strategies in the near future.

Keywords： pharmacogenomics acute lymphoblastic leukemia genomics pharmacogenetics